Shilpa Medicare Ltd
Company Profile
Business description
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
Contact
Hyderabad Road
No. 12-6-214/A-1, Shilpa House
RaichurKA584135
INDT: +91 8532238704
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
998
Stocks News & Analysis
stocks
Beaten down real estate share receives legal blow
stocks
OpenAI joins the mega-AI lab IPO race, but timing is uncertain
stocks
What happens if Tesla and SpaceX merge?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,005.90 | 28.90 | 0.32% |
| CAC 40 | 8,200.80 | 38.97 | 0.48% |
| DAX 40 | 24,209.71 | 14.40 | 0.06% |
| Dow JONES (US) | 50,848.75 | 929.97 | 1.86% |
| FTSE 100 | 10,303.88 | 49.07 | 0.48% |
| HKSE | 24,649.65 | 400.36 | 1.65% |
| NASDAQ | 25,809.66 | 640.16 | 2.54% |
| Nikkei 225 | 66,727.83 | 2,510.56 | 3.91% |
| NZX 50 Index | 13,345.76 | 143.60 | 1.09% |
| S&P 500 | 7,394.30 | 127.31 | 1.75% |
| S&P/ASX 200 | 8,802.90 | 29.40 | 0.34% |
| SSE Composite Index | 4,034.59 | 47.58 | 1.19% |